Biological activities of extracts and compounds from Thai Kae-Lae (Maclura cochinchinensis (Lour.) Corner).
Anti-inflammation
Anti-leukaemia
Antioxidant
Cancer prevention
Fractional extract
Maclura cochinchinensis (Lour.) Corner
Resveratrol
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
09 Jun 2023
09 Jun 2023
Historique:
received:
30
01
2023
accepted:
27
04
2023
medline:
12
6
2023
pubmed:
10
6
2023
entrez:
9
6
2023
Statut:
epublish
Résumé
The purpose of this study was to investigate the biological properties of Kae-Lae (Maclura cochinchinensis (Lour.) Corner), a traditional medicinal plant used in Ayurvedic recipes in Thailand. To achieve this objective, heartwood samples were collected from 12 sources across Thailand. Fractional extracts (n-hexane, ethyl acetate, and ethanol) and the dominant compounds (morin, resveratrol, and quercetin) were examined for their abilities on cytotoxicity, antioxidant, anti-inflammation, and antileukaemic activity (Wilms' tumour 1 protein was used as a well-known biomarker for leukaemic cell proliferation). The study used MTT to assess cytotoxicity in leukaemic cells (K562, EoL-1, and KG-1a). Antioxidant activities were evaluated using ABTS, DPPH, and FRAP assays. The anti-inflammatory activity was investigated by detecting IL-2, TNF-α, and NO using appropriate detection kits. Wilms' tumour 1 protein expression was measured by Western blotting to determine the anti-leukaemic activity. The inhibition of cell migration was also analyzed to confirm anticancer progression. Among the tested extract fraction, ethyl acetate No. 001 displayed strong cytotoxicity specifically in EoL-1 cells, while n-hexane No. 008 demonstrated this effect in three cell lines. Resveratrol, on the other hand, displayed cytotoxicity in all the tested cells. Additionally, the three major compounds, morin, resveratrol, and quercetin, exhibited significant antioxidant and anti-inflammatory properties. In particular, resveratrol demonstrated a noteworthy decreased Wilms' tumour 1 protein expression and a reduction in cell proliferation across all cells. Moreover, ethyl acetate No. 001, morin, and resveratrol effectively inhibited MCF-7 cell migration. None of these compounds showed any impact on red blood cell haemolysis. Based on these findings, it can be concluded that Kae-Lae has promising chemotherapeutic potential against leukaemic cells, with fractional extracts (ethyl acetate and n-hexane) and resveratrol exhibiting the most potent cytotoxic, antioxidant, anti-inflammatory, and anti-cell migration activities.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
The purpose of this study was to investigate the biological properties of Kae-Lae (Maclura cochinchinensis (Lour.) Corner), a traditional medicinal plant used in Ayurvedic recipes in Thailand. To achieve this objective, heartwood samples were collected from 12 sources across Thailand. Fractional extracts (n-hexane, ethyl acetate, and ethanol) and the dominant compounds (morin, resveratrol, and quercetin) were examined for their abilities on cytotoxicity, antioxidant, anti-inflammation, and antileukaemic activity (Wilms' tumour 1 protein was used as a well-known biomarker for leukaemic cell proliferation).
METHODS
METHODS
The study used MTT to assess cytotoxicity in leukaemic cells (K562, EoL-1, and KG-1a). Antioxidant activities were evaluated using ABTS, DPPH, and FRAP assays. The anti-inflammatory activity was investigated by detecting IL-2, TNF-α, and NO using appropriate detection kits. Wilms' tumour 1 protein expression was measured by Western blotting to determine the anti-leukaemic activity. The inhibition of cell migration was also analyzed to confirm anticancer progression.
RESULTS
RESULTS
Among the tested extract fraction, ethyl acetate No. 001 displayed strong cytotoxicity specifically in EoL-1 cells, while n-hexane No. 008 demonstrated this effect in three cell lines. Resveratrol, on the other hand, displayed cytotoxicity in all the tested cells. Additionally, the three major compounds, morin, resveratrol, and quercetin, exhibited significant antioxidant and anti-inflammatory properties. In particular, resveratrol demonstrated a noteworthy decreased Wilms' tumour 1 protein expression and a reduction in cell proliferation across all cells. Moreover, ethyl acetate No. 001, morin, and resveratrol effectively inhibited MCF-7 cell migration. None of these compounds showed any impact on red blood cell haemolysis.
CONCLUSION
CONCLUSIONS
Based on these findings, it can be concluded that Kae-Lae has promising chemotherapeutic potential against leukaemic cells, with fractional extracts (ethyl acetate and n-hexane) and resveratrol exhibiting the most potent cytotoxic, antioxidant, anti-inflammatory, and anti-cell migration activities.
Identifiants
pubmed: 37296375
doi: 10.1186/s12906-023-03979-w
pii: 10.1186/s12906-023-03979-w
pmc: PMC10257291
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antioxidants
0
ethyl acetate
76845O8NMZ
Flavonoids
0
n-hexane
2DDG612ED8
Plant Extracts
0
Quercetin
9IKM0I5T1E
Resveratrol
Q369O8926L
WT1 Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
191Informations de copyright
© 2023. The Author(s).
Références
Oxid Med Cell Longev. 2022 Feb 14;2022:8214821
pubmed: 35198096
Biochem Biophys Res Commun. 2009 Feb 6;379(2):632-6
pubmed: 19121625
Int J Mol Sci. 2014 Dec 30;16(1):645-59
pubmed: 25561222
Nutrients. 2017 Oct 10;9(10):
pubmed: 28994714
Cell Biol Toxicol. 2011 Dec;27(6):413-23
pubmed: 21766178
Int J Mol Sci. 2013 Jul 12;14(7):14620-46
pubmed: 23857058
Int J Mol Sci. 2017 Dec 01;18(12):
pubmed: 29194365
Anticancer Res. 2007 Jan-Feb;27(1A):395-405
pubmed: 17352259
BMC Complement Altern Med. 2017 Jun 13;17(1):309
pubmed: 28610607
Leukemia. 2004 Aug;18(8):1380-90
pubmed: 15201848
Mol Nutr Food Res. 2008 Jun;52(6):683-91
pubmed: 18398872
Molecules. 2020 Nov 23;25(22):
pubmed: 33238470
Cancer Lett. 2006 May 8;236(1):13-23
pubmed: 15978720
Clin Transl Med. 2013 Jan 17;2(1):3
pubmed: 23369605
J Tradit Complement Med. 2019 Mar 09;10(1):85-94
pubmed: 31956562
Endocr Relat Cancer. 2014 May 06;21(3):R209-25
pubmed: 24500760
Cancer. 1989 Aug 1;64(3):598-604
pubmed: 2743254
Bioorg Med Chem Lett. 2018 Feb 1;28(3):410-414
pubmed: 29274817
Ann Hematol. 2009 Dec;88(12):1199-205
pubmed: 19404640
Cancer Chemother Pharmacol. 2008 Sep;62(4):585-94
pubmed: 18034345
N Engl J Med. 2006 Sep 21;355(12):1253-61
pubmed: 16990388
Biofactors. 2000;13(1-4):67-72
pubmed: 11237202
Mediators Inflamm. 2014;2014:507272
pubmed: 24891766
Nat Prod Res. 2021 Dec;35(23):5554-5558
pubmed: 32674703
Leukemia. 2003 Jul;17(7):1301-12
pubmed: 12835718
Haematologica. 2004 Aug;89(8):926-33
pubmed: 15339675
Nat Med. 1997 Jul;3(7):730-7
pubmed: 9212098
Antioxidants (Basel). 2019 Nov 21;8(12):
pubmed: 31766492
Leuk Lymphoma. 1997 May;25(5-6):435-43
pubmed: 9250813
Oxid Med Cell Longev. 2022 Feb 3;2022:2041769
pubmed: 36824615
BMC Complement Altern Med. 2016 Jul 29;16:258
pubmed: 27473625
Pharmaceutics. 2022 Oct 04;14(10):
pubmed: 36297550
Antioxid Redox Signal. 2015 Jun 1;22(16):1382-424
pubmed: 25364882
Clin Cancer Res. 2005 Sep 15;11(18):6520-7
pubmed: 16166428
In Vivo. 2014 Sep-Oct;28(5):675-81
pubmed: 25189877
Cancer Lett. 2008 Apr 18;262(2):153-63
pubmed: 18314259
Curr Neuropharmacol. 2009 Mar;7(1):65-74
pubmed: 19721819
Front Pharmacol. 2020 Dec 10;11:534171
pubmed: 33362534
Biochem Pharmacol. 2008 Oct 15;76(8):967-73
pubmed: 18755157
Cancer Biol Ther. 2012 May;13(7):516-26
pubmed: 22406996
Cancer Biol Ther. 2014 Apr;15(4):473-8
pubmed: 24496081
FEBS Lett. 1997 Jun 2;409(1):41-5
pubmed: 9199500
Cell Signal. 2019 Jan;53:339-347
pubmed: 30395942
Int J Mol Sci. 2022 Aug 12;23(16):
pubmed: 36012254
Nutr Cancer. 2019;71(7):1189-1200
pubmed: 30955364
Cytotherapy. 2005;7(1):57-61
pubmed: 16040384
Lancet. 2004 Oct 2-8;364(9441):1219-28
pubmed: 15464182
Oncotarget. 2016 Jul 19;7(29):45489-45499
pubmed: 27329589
Blood. 2002 Jan 1;99(1):319-25
pubmed: 11756187
Leukemia. 2013 Apr;27(5):1204-1207
pubmed: 23086103
Mol Nutr Food Res. 2012 May;56(5):725-32
pubmed: 22648619
Adv Hematol. 2014;2014:103175
pubmed: 24778653
J Chromatogr Sci. 2017 Mar 1;55(3):346-350
pubmed: 27974355
Am J Cancer Res. 2017 Mar 01;7(3):417-432
pubmed: 28401001
J Cell Physiol. 2019 Aug;234(8):13233-13241
pubmed: 30589076
Oncol Rep. 2021 Jul;46(1):
pubmed: 33982761
Front Biosci (Landmark Ed). 2022 Jun 21;27(6):197
pubmed: 35748273
Chem Biol Interact. 2019 Jun 1;306:29-38
pubmed: 30954463
Jpn J Clin Oncol. 2010 May;40(5):377-87
pubmed: 20395243
Curr Pharmacol Rep. 2015 Feb 1;1(1):46-51
pubmed: 25774338